Alzheimer's disease

Discovery may be key to Alzheimer's treatment

March 20, 2014
Bloomberg News
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
More

U.S. venture gathers drugmakers to take on major diseases

February 4, 2014
Bloomberg News
Eli Lilly and Co., Pfizer Inc. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
More

Lilly foe still testing Alzheimer's theory where others failed

December 12, 2013
Bloomberg News
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
More

Alzheimer’s targeted in $45M government study grant

September 18, 2013
Bloomberg News
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer's.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Feds mull covering Alzheimer's test that uses Lilly's Amyvid

July 1, 2013
Bloomberg News
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
More

Lilly wins patent lawsuit on J&J Alzheimer’s research

June 25, 2013
Bloomberg News
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
More

Lilly halts trial of experimental Alzheimers drug

June 14, 2013
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
More

Lilly study: 1 in 5 Alzheimer's patients misdiagnosed

May 20, 2013
J.K. Wall
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
More

Lilly suing J&J for patent rights in Alzheimer's drug race

April 25, 2013
Bloomberg News
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
More

New $100M plan to map human brain could boost Lilly

April 2, 2013
Bloomberg News
President Obama on Tuesday announced a campaign designed to develop treatments for some of the least understood brain disorders, an effort that could benefit health care giants Eli Lilly and Co. and others.
More

Lilly's Alzheimer’s effort may gain from brain-mapping plan

February 18, 2013
Bloomberg News
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
More

Lilly drug chosen for Alzheimer's prevention study

January 18, 2013
Associated Press
Researchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.
More

Lilly's Amyvid receives European approval

January 16, 2013
Associated Press
European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.
More

Lilly finds solace in new Alzheimer's study

December 17, 2012
J.K. Wall
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
More

Alzheimer’s prevention seen promising as drug cures fail

October 19, 2012
Bloomberg News
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
More

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

October 10, 2012
Bloomberg News
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
More

Lilly shares rise on Alzheimer's study results

October 8, 2012
J.K. Wall
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
More

New Alzheimer's unit stresses soothing elements

October 6, 2012
Scott Olson
The 36-room wing at Hoosier Village Retirement Center includes antiques and minimizes confusing shadows among other design elements.
More

Lilly's Alzheimer's finding triggers investor hope, doctor caution

August 27, 2012
Bloomberg News
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
More

Alzheimer's drug results leave Lilly 'excited' but uncertain

August 24, 2012
J.K. Wall
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
More

Lilly's Alzheimer's drug trials show mixed results

August 24, 2012
Bloomberg News, J.K. Wall
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
More

Alzheimer's quest puts Lilly to test

August 11, 2012
J.K. Wall
Odds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
More

Lilly stock slips after competitors halt Alzheimer's plans

August 7, 2012
 IBJ Staff and Bloomberg News
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
More

Potential Alzheimer’s drug fails first of four key trials

July 24, 2012
Bloomberg News
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
More
Page  1 2 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT